Navigation Links
Johnson & Johnson and Crucell Reach Agreement on Intended Public Offer of Euro 24.75 per Ordinary Share of Crucell
Date:10/5/2010

NEW BRUNSWICK, N.J. and LEIDEN, Netherlands, Oct. 6 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) and Crucell N.V. (NYSE Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced an agreement whereby Johnson & Johnson, through an affiliate, would acquire all outstanding equity of Crucell that it does not already own for approximately euro 1.75 billion in a recommended cash tender offer (the Offer).

Crucell is a global biopharmaceutical company focused on the research & development, production and marketing of vaccines and antibodies against infectious disease worldwide. The Company currently markets vaccines in the paediatric, travel, endemic and respiratory fields and has several vaccines in clinical development.

After consummation of the Offer Johnson & Johnson expects to maintain Crucell's existing facilities, to retain Crucell's senior management and, generally, to maintain current employment levels. Johnson & Johnson also intends to keep Crucell as the center for vaccines within the Johnson & Johnson pharmaceutical group, and to maintain Crucell's headquarters in Leiden.

Johnson & Johnson currently owns 17.9% of Crucell's outstanding shares. In addition, in September 2009 Johnson & Johnson entered into an agreement with Crucell to develop a universal influenza monoclonal antibody and a universal flu vaccine for the treatment and prevention of influenza, as well as a long-term innovation collaboration for the development of monoclonal antibodies and/or vaccines directed against up to three other infectious and non-infectious disease targets.

"Johnson & Johnson and Crucell share a commitment to improving the lives of people worldwide," said Paul Stoffels, Global Head, Pharmaceutical Research and Development, Johnson & Jo
'/>"/>

SOURCE Johnson & Johnson
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. aTyr Pharma Appoints Catharine E. Johnson As Senior Vice President of Business Development
2. Johnson & Johnson Consumer Companies, Inc., Unveils CYTOMIMIC(TM) Technology at 68th Annual Meeting of the American Academy of Dermatology
3. Johnson & Johnson Honors 2009 Recipient of The Dr. Paul Janssen Award for Biomedical Research
4. Cempra Pharmaceuticals Announces Appointment of John H. Johnson to Board of Directors
5. Johnson & Johnson Completes Acquisition of Cougar Biotechnology
6. Johnson & Johnson Completes Initial Tender Offer for Cougar Biotechnology
7. Johnson & Johnson Announces Regulatory Clearance for Its Planned Acquisition of Cougar Biotechnology
8. Johnson & Johnson Begins Tender Offer to Acquire Cougar Biotechnology
9. Johnson & Johnson Announces Definitive Agreement to Acquire Cougar Biotechnology, Inc.
10. Simbionix and Johnson & Johnson LLC Announce a Distribution Agreement for Russia and the CIS Countries
11. Burnham Announces Assay Development and License Agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Bill Jacobs Automotive, a group of ... teaming up with the Heartland Blood Center and offering free ... The drive takes place Saturday, Jan. 18 at the Bill ... p.m. (Photo: http://photos.prnewswire.com/prnh/20140115/MN46637 )  The ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 Cynvenio, a ... management through the genomic analysis of tumor cells in ... Finder™, a web-based cancer decision support application powered by ... with Cynvenio’s ClearID™ genomic test, Therapy Finder will provide ...
(Date:1/15/2014)... A study has been launched to test whether ... could help to tackle the problem of obesity.  This unique ... surgery based in Stowmarket) and academics at University Campus Suffolk ... technology, which is inspired by equipment used to collect data ...
(Date:1/15/2014)... 2014 DTS Language Services, Inc . ... Portal for Life Science organizations who need document translations. ... matter of their documents in advance with a selection of ... of translations, often a critical factor in clinical and scientific ...
Breaking Biology Technology:Join the Bill Jacobs Auto blood drive and receive a free oil change 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2
... Pa., Sept. 7, 2011 Tengion, Inc (NASDAQ: ... Brian Davis, Vice President and Chief Financial Officer of Tengion, ... Healthcare Conference on Tuesday, September 13, 2011, at 1:35 pm ... can be accessed under "Calendar of Events" in the Investors ...
... 2011 The Journal of Cell Biology ... pleased to announce their next enhancement to the JCB ... published scientific image data. Starting today, data from genome-wide ... with papers published in JCB. HCS data are increasingly ...
... 7, 2011 Debiopharm Group™ ... focuses on serious medical conditions and particularly ... privately-held, biopharmaceutical company dedicated to the discovery ... cancer, have entered into an exclusive worldwide ...
Cached Biology Technology:Tengion to Present at Rodman & Renshaw 13th Annual Healthcare Conference 2Glencoe Software and The Journal of Cell Biology Pioneer Publishing of Genome-Wide Screens 2Glencoe Software and The Journal of Cell Biology Pioneer Publishing of Genome-Wide Screens 3Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T 2Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T 3
(Date:4/16/2014)... ,, Sometimes known as Kennedy,s disease, spinal and bulbar muscular ... slowly progressive muscle weakness and atrophy. Researchers have long considered ... the cells in the spinal cord and brainstem that ... in the April 16, 2014 online issue of Neuron ...
(Date:4/16/2014)... thoughts and feelings are the result of neurons talking ... of the conversations might not be all that private. Brain ... even participating in, some of those discussions. But a new ... part of the time specifically, when the neurons get ...
(Date:4/16/2014)... Klaus Aktories and Dr. Panagiotis Papatheodorou from the Institute of ... Freiburg have discovered the receptor responsible for smuggling the toxin ... The TpeL toxin, which is formed by C. perfringens ... It is very similar to the toxins of many other ...
Breaking Biology News(10 mins):Mutant protein in muscle linked to neuromuscular disorder 2Eavesdropping on brain cell chatter 2Eavesdropping on brain cell chatter 3Gate for bacterial toxins found 2
... the president of Conservation International and a global leader ... Medal from the Harvard Museum of Natural History. ... who has written more than 500 scientific and popular ... has described 11 species new to science, had seven ...
... Scientists at UC Santa Barbara have made a significant discovery ... They explain nature,s way of controlling whether these cells will ... a liver, or any other part of the human body. ... the journal Cell . The scientists say the ...
... a successful second funding period, the first three DFG ... for another four years. This decision was made by ... Research Foundation) at its spring session in Bonn. As ... in the Earth System" in Bremen, "The Center for ...
Cached Biology News:Scientists shed light on inner workings of human embryonic stem cells 2Scientists shed light on inner workings of human embryonic stem cells 3The first DFG research centers to be funded for another four years 2The first DFG research centers to be funded for another four years 3The first DFG research centers to be funded for another four years 4
... in the submicron range are part of ... and control of particle size is important ... can reliably detect the component populations in ... Particle Size Analyzer uses Photon Correlation Spectroscopy ...
...
... a dedicated system for SFC and SFE ... of HPLC instrumentation. JASCO has recently added ... of the system: ,- The PU-1580-CO2 delivery ... procedures using carbon dioxide as the mobile ...
... ( Abpromise for all tested ... Synthetic peptide: IGPEVPDDRDFEPS conjugated to KLH, ... Human Decorin (fragment 36-49 of the ... Entrez GeneID: 1634 ...
Biology Products: